Centessa Pharmaceuticals plc EBIT

Centessa Pharmaceuticals plc (CNTA) currently reports a EBIT of $-270M as of March 2026. That compares with $-230M in the prior-year period — down 17.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Centessa Pharmaceuticals plc's EBIT history and peer comparisons.

Centessa Pharmaceuticals plc's EBIT decreased from $-230M to $-270M — a 17.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Centessa Pharmaceuticals plc's EBIT of $-270M is lower than the Healthcare sector average of $22B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Centessa Pharmaceuticals plc reported $-270M in EBIT as of March 2026. That compares with $-230M in the prior-year period — down 17.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-270M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Centessa Pharmaceuticals plc, and consider following CNTA for alerts when major investors trade the stock.